544 related articles for article (PubMed ID: 27179310)
1. Platelet reactivity in patients receiving a maintenance dose of P2Y12-ADP receptor antagonists undergoing elective percutaneous coronary intervention.
Bonello L; Laine M; Thuny F; Paganelli F; Lemesle G; Roch A; Kerbaul F; Dignat-George F; Berbis J; Frere C
Int J Cardiol; 2016 Aug; 216():190-3. PubMed ID: 27179310
[TBL] [Abstract][Full Text] [Related]
2. Platelet reactivity evaluated with the VASP assay following ticagrelor loading dose in acute coronary syndrome patients undergoing percutaneous coronary intervention.
Laine M; Toesca R; Berbis J; Frere C; Barnay P; Pansieri M; Peyre JP; Michelet P; Bessereau J; Camilleri E; Helaf O; Camaleonte M; Paganelli F; Dignat-George F; Bonello L
Thromb Res; 2013 Jul; 132(1):e15-8. PubMed ID: 23726090
[TBL] [Abstract][Full Text] [Related]
3. Effects of Ticagrelor Versus Clopidogrel in Troponin-Negative Patients With Low-Risk ACS Undergoing Ad Hoc PCI.
Angiolillo DJ; Franchi F; Waksman R; Sweeny JM; Raveendran G; Teng R; Zhao Y; Carlson G; Khan N; Mehran R
J Am Coll Cardiol; 2016 Feb; 67(6):603-613. PubMed ID: 26868683
[TBL] [Abstract][Full Text] [Related]
4. Onset of optimal P2Y12-ADP receptor blockade after ticagrelor and prasugrel intake in Non-ST elevation acute coronary syndrome.
Bonello L; Laine M; Camoin-Jau L; Noirot F; Guieu R; Dignat-George F; Paganelli F; Frere C
Thromb Haemost; 2015 Oct; 114(4):702-7. PubMed ID: 26311415
[TBL] [Abstract][Full Text] [Related]
5. Platelet reactivity in diabetic patients undergoing coronary stenting for acute coronary syndrome treated with clopidogrel loading dose followed by prasugrel maintenance therapy.
Cuisset T; Gaborit B; Dubois N; Quilici J; Loosveld M; Beguin S; Loundou AD; Moro PJ; Morange PE; Alessi MC; Dutour A; Bonnet JL
Int J Cardiol; 2013 Sep; 168(1):523-8. PubMed ID: 23084816
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of ex vivo autologous and in vivo platelet transfusion in the reversal of P2Y12 inhibition by clopidogrel, prasugrel, and ticagrelor: the APTITUDE study.
O'Connor SA; Amour J; Mercadier A; Martin R; Kerneis M; Abtan J; Brugier D; Silvain J; Barthélémy O; Leprince P; Montalescot G; Collet JP;
Circ Cardiovasc Interv; 2015 Nov; 8(11):e002786. PubMed ID: 26553698
[TBL] [Abstract][Full Text] [Related]
7. Administration of Ticagrelor and Double-Dose Clopidogrel Based on Platelet Reactivity Determined by VerifyNow-P2Y12 for Chinese Subjects After Elective PCI.
Wu X; Liu G; Lu J; Zheng XX; Cui JG; Zhao XY; Huang XH
Int Heart J; 2017 Apr; 58(2):167-173. PubMed ID: 28321022
[TBL] [Abstract][Full Text] [Related]
8. Ticagrelor versus prasugrel in patients with high on-clopidogrel treatment platelet reactivity after PCI: The ISAR-ADAPT-PF study.
Bernlochner I; Mayer K; Orban M; Morath T; Jaitner J; Rössner L; Gross L; Laugwitz KL; Kastrati A; Sibbing D
Platelets; 2016 Dec; 27(8):796-804. PubMed ID: 27275651
[TBL] [Abstract][Full Text] [Related]
9. Assessment of P2Y12 inhibitor usage and switching in acute coronary syndrome patients undergoing percutaneous coronary revascularization.
Kudaravalli M; Althouse AD; Marroquin OC; Khandhar SJ; Sharbaugh MS; Toma C; Conrad Smith AJ; Schindler JT; Lee JS; Mulukutla SR
Int J Cardiol; 2016 Nov; 223():854-859. PubMed ID: 27592042
[TBL] [Abstract][Full Text] [Related]
10. Ticagrelor increases endothelial progenitor cell level compared to clopidogrel in acute coronary syndromes: A prospective randomized study.
Bonello L; Frere C; Cointe S; Laine M; Mancini J; Thuny F; Kerbaul F; Lemesle G; Paganelli F; Guieu R; Arnaud L; Dignat-George F; Sabatier F
Int J Cardiol; 2015; 187():502-7. PubMed ID: 25846661
[TBL] [Abstract][Full Text] [Related]
11. Latest evidence in personalized antiplatelet therapy in patients with acute coronary syndromes undergoing percutaneous coronary intervention.
Uhry S; Bessereau J; Camoin-Jau L; Paganelli F; Bonello L
Hosp Pract (1995); 2012 Apr; 40(2):104-17. PubMed ID: 22615085
[TBL] [Abstract][Full Text] [Related]
12. High and low on-treatment platelet reactivity to P2Y
Ferreiro JL; Vivas D; De La Hera JM; Marcano AL; Lugo LM; Gómez-Polo JC; Silva I; Tello-Montoliu A; Marín F; Roldán I
Thromb Res; 2019 Mar; 175():95-101. PubMed ID: 30738371
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the Antiplatelet Effects of Once and Twice Daily Low-Dose Ticagrelor and Clopidogrel After Percutaneous Coronary Intervention.
Choi KN; Jin HY; Shin HC; Park YA; Seo JS; Jang JS; Yang TH; Kim DK; Kim DS
Am J Cardiol; 2017 Jul; 120(2):201-206. PubMed ID: 28554486
[TBL] [Abstract][Full Text] [Related]
14. Design and Rationale of the APELOT Trial: A Randomized, Open-Label, Multicenter, Phase IV Study to Evaluate the Antiplatelet Effect of Different Loading Dose of Ticagrelor in Patients With Non-ST Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention.
Liu HL; Wei YJ; Jin ZG; Zhang J; Ding P; Yang SL; Luo JP; Ma DX; Liu Y; Han W
Medicine (Baltimore); 2016 May; 95(22):e3756. PubMed ID: 27258504
[TBL] [Abstract][Full Text] [Related]
15. Angiographic outcomes in the PLATO Trial (Platelet Inhibition and Patient Outcomes).
Kunadian V; James SK; Wojdyla DM; Zorkun C; Wu J; Storey RF; Steg PG; Katus H; Emanuelsson H; Horrow J; Maya J; Wallentin L; Harrington RA; Gibson CM
JACC Cardiovasc Interv; 2013 Jul; 6(7):671-83. PubMed ID: 23866179
[TBL] [Abstract][Full Text] [Related]
16. Impact of Diabetes Mellitus on the Pharmacodynamic Effects of Ticagrelor Versus Clopidogrel in Troponin-Negative Acute Coronary Syndrome Patients Undergoing Ad Hoc Percutaneous Coronary Intervention.
Sweeny JM; Angiolillo DJ; Franchi F; Rollini F; Waksman R; Raveendran G; Dangas G; Khan ND; Carlson GF; Zhao Y; Teng R; Mehran R
J Am Heart Assoc; 2017 Mar; 6(4):. PubMed ID: 28356282
[TBL] [Abstract][Full Text] [Related]
17. Evolving pattern of platelet P2Y12 inhibition in patients with acute coronary syndromes.
Joshi RR; Hossain R; Morton AC; Ecob R; Judge HM; Wales C; Walker JV; Karunakaran A; Storey RF
Platelets; 2014; 25(6):416-22. PubMed ID: 24111601
[TBL] [Abstract][Full Text] [Related]
18. Ticagrelor versus prasugrel in acute coronary syndrome patients with high on-clopidogrel platelet reactivity following percutaneous coronary intervention: a pharmacodynamic study.
Alexopoulos D; Galati A; Xanthopoulou I; Mavronasiou E; Kassimis G; Theodoropoulos KC; Makris G; Damelou A; Tsigkas G; Hahalis G; Davlouros P
J Am Coll Cardiol; 2012 Jul; 60(3):193-9. PubMed ID: 22789884
[TBL] [Abstract][Full Text] [Related]
19. Factors associated with the failure of clopidogrel dose-adjustment according to platelet reactivity monitoring to optimize P2Y12-ADP receptor blockade.
Bonello L; Camoin-Jau L; Mancini J; Bessereau J; Grosdidier C; Alessi MC; Ostorero M; Dignat-George F; Paganelli F
Thromb Res; 2012 Jul; 130(1):70-4. PubMed ID: 22285300
[TBL] [Abstract][Full Text] [Related]
20. Platelet-related biomarkers and their response to inhibition with aspirin and p2y
Lowenstern A; Storey RF; Neely M; Sun JL; Angiolillo DJ; Cannon CP; Himmelmann A; Huber K; James SK; Katus HA; Morais J; Siegbahn A; Steg PG; Wallentin L; Becker RC;
J Thromb Thrombolysis; 2017 Aug; 44(2):145-153. PubMed ID: 28608165
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
